Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion

• Published in: Arrhythmia & electrophysiology review 2013-11, Vol.2 (2), p.109-114
• Main Authors: Zografos, Theodoros A, Katritsis, Demosthenes G
• Format: Article
• Language: English
• Subjects: Amino acids; Cardiac arrhythmia; Cardiovascular disease; Cardioversion; Clinical Arrhythmias; Gene expression; Insulin-like growth factors; Ligands; Mammals; Peptides; Plasma; Thoracic surgery; Tumor necrosis factor-TNF
• ISSN: 2050-3369; 2050-3377; 2050-3377
• DOI: 10.15420/aer.2013.2.2.109

Electrical cardioversion (ECV) can be effective in restoring sinus rhythm (SR) in the majority of patients with atrial fibrillation (AF). Several factors that predispose to AF recurrences, such as age, AF duration and left atrial size have been used to guide a decision for cardioversion, but increasing evidence suggests that they may be rather poor markers of left atrial structural remodeling that determines the long-term success of a rhythm control strategy. In this context, the use of easily obtainable biomarkers, such as the levels of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), to predict AF recurrences may be preferable. Since ANP production is associated with the extent of functional atrial myocardium, and both ANP and BNP reflect atrial pressure and mechanical stretching, these peptides are good candidate biomarkers to assess predisposition to AF recurrences. In this review we focus on the pathophysiological mechanisms and the available clinical evidence regarding the prediction of AF recurrences following successful ECV from pre-procedural ANP and BNP levels.